TEMPLATE CASE REPORT FORM. Rapid Response Pharmacovigilance in Palliative Care
|
|
- Meghan Williams
- 5 years ago
- Views:
Transcription
1 TEMPLATE CASE REPORT FORM Rapid Response Pharmacovigilance in Palliative Care The case report form is to be completed in compliance with PaCCSC Standard Operating Procedures 1
2 Staff Participant Id: Date of Baseline: Demographics Gender Male Female Age years Weight (kg) estimated Height (cm) estimated Primary Life Limiting Illness Advanced cancer End stage renal failure Hepatic failure Neurodegenerative disease Other (please specify) AIDS Cardiac failure Respiratory failure Ischaemic heart disease Palliative Care Phase Stable Unstable Deteriorating Terminal 2
3 Laboratory tests (Only if available) Result Not Collected International normalised ratio (INR) Platelets Hb Urea Creatinine egfr Charlson Comorbidity Index Conditions: Myocardial infarct Congestive cardiac failure Peripheral vascular disease Cerebrovascular disease Dementia Chronic pulmonary disease Connective tissue disease Ulcer disease Mild liver disease Diabetes Hemiplegia Moderate or severe renal disease Diabetes with end organ damage Any tumour Leukaemia Lymphoma Moderate or severe liver disease Metastatic solid tumour AIDS 3
4 Australian Modified Karnofsky Performance Scale (AKPS) = Normal; no complaints; no evidence of disease. 90 = Able to carry on normal activity; minor signs or symptoms. 80 = Normal activity with effort; some signs of symptoms or disease. 70 = Cares for self; unable to carry on normal activity or to do active work. 60 = Requires occasional assistance but is able to care for most of his needs. 50 = Requires considerable assistance and frequent medical care. 40 = In bed more than 50% of the time. 30 = Almost completely bedfast. 20 = Totally bedfast and requiring extensive nursing care by professionals and/or family. 10 = Comatose or barely rouseable. 0 = Dead Not able to determine 4
5 T0 Baseline Medication Commencement Date: Time: Symptom of Interest Symptom Severity Score NCI Criteria Here Toxicity assessment SYMPTOM Ungradable No Symptom Other 1-please specify Other 2-please specify Other 1-please specify Other 2-please specify
6 T1- No of hours/days after commencement (to be decided by subcommittee) Current medication dose Drug Dose (mgs) Route Frequency (eg. Mane, nocte, bd, tds, over 24hrs) Symptom Severity Score NCI Criteria Here Toxicity assessment SYMPTOM Ungradable No Symptom Other 1-please specify Other 2-please specify Other 1-please specify Other 2-please specify Which toxicity is the most troublesome? Select: If there were toxicities, were any given a grade of 3 or more? t applicable 6
7 T1- Symptomatic Benefit Assessment - (Time from T0 T1) Assessed / Not assessed reason Assessed today (continue) t able to be contacted / located Too unwell Other Date of assessment Total dose given in last 24 hours (mgs) How long has the patient been on this dose (days) Select: (insert drop down box 1-14 days) Was there any benefit? Medication Changes Medication of interest dose maintained/continue current dose Medication of interest dose increased (please specify below) Medication of interest dose decreased Medication of interest dose ceased New medication added (please specify below) If "new medication added" above, please specify here If "medication of interest dose increased" above, please specify new dose mgs 7
8 T2- Assessment ( Date of Assessment --/--/-- Current medication dose Drug Dose (mgs) Route Frequency (eg. Mane, nocte, bd, tds, over 24hrs) Symptom Severity Score NCI Criteria Here Toxicity assessment SYMPTOM Ungradable No Symptom Other 1-please specify Other 2-please specify Other 1-please specify Other 2-please specify Which toxicity is the most troublesome? Select: If there were toxicities, were any given a grade of 3 or more? t applicable 8
9 T2- Symptomatic Benefit Assessment - Assessed / Not assessed reason Assessed today (continue) t able to be contacted / located Too unwell Other Date of assessment Total dose given in last 24 hours (mgs) How long has the patient been on this dose (days) Select: (insert drop down box 1-14 days) Was there any benefit? Medication Changes Medication of interest dose maintained/continue current dose Medication of interest dose increased (please specify below) Medication of interest dose decreased Medication of interest dose ceased New medication added (please specify below) If "new medication added" above, please specify here If "medication of interest dose increased" above, please specify new dose mgs 9
10 What is the intended treatment based on the assessment today? change to medication of interest/continue current dose Medication of interest ceased Medication of interest reduced Medication of interest dose increased (please specify new dose) Has a medication been added to treat a specific toxicity? Based on the assessment today has toxicity resolved? N/A Key questions derived from the Naranjo check list (only complete this section if any toxicity on the previous page is 3 or greater) 1. Did the adverse reaction appear after the suspected drug was given? Yes Don't know 2. Did the adverse reaction improve when the drug was discontinued or a specific antagonist was given? 3. Are there alternative causes (other than the drug) that could on their own have caused the reaction? Don't know 4. Did the patient have a similar reaction to the same or similar drug in any previous exposure? Don't know 5. Was the adverse event confirmed by any objective evidence? No Don't know 10
11 Medication Cessation (complete this page at any time the medication of interest is ceased) Date of assessment (medication cessation) Medication was ceased (related to indication of interest): Symptom resolved (provide date, question a) Symptom continued unchanged Symptom worsened (please specify, question b) Medication was ceased (related to other reasons): Toxicity - refer to unscheduled toxicity assessment Patient unable to take medication (go to question c) Other - please specify What treatment did you subsequently initiate following cessation of the medication of interest? a) Symptom resolved - date of resolution Date: b) Symptom worsened - Grade (NCI) c) Patient unable to take medication please specify 11
12 Unscheduled Adverse Event Assessment (a) Please list any symptomatic adverse events that occur at any time regardless of whether they are attributable to the medication of interest or not. Were there any symptomatic adverse events? Y Symptom Severity Score Toxicities Specify any adverse drug event and grade it according to NCI criteria Toxicity assessment SYMPTOM Ungradable No Symptom Other 1 Other 2 Other 1 please specify Other 2 please specify Which toxicity is the most troublesome? Select: If there were toxicities, were any given a grade of 3 or more? t applicable 12
Midazolam for Agitation - Baseline
Midazolam for Agitation - Baseline Staff email Participant ID Date of Baseline w D-M-Y H:M Initials of person entering data Demographics Gender Male Female Age Weight (kg) Height (cm) Page 1 Primary life
More informationANAMORELIN FOR CACHEXIA. Series 20 CASE REPORT FORM
1 ANAMORELIN FOR CACHEXIA Series 20 CASE REPORT FORM Palliative Care Clinical Studies Collaborative (PaCCSC) RAPID Pharmacovigilance in Palliative Care The case report form (CRF) is to be completed in
More informationLABs Albumin. (g/dl) Haemoglobin, (g/l) Creatinin, (mg/dl)
DATA COLLECTION SHEET CRF B Baseline evaluation Center ID: Patient code: Date of birth (dd/mm/yyyy): / / Sex: Male Female Living situation: home independent home with family/care giver residential care
More informationIntestinal Failure Referral Form
Intestinal Failure Referral Form This form must be completed in full and emailed to UCLH.IFReferrals@nhs.net or call 07958 263178. Please complete all sections of the form. Please note that incomplete
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationRisk of Fractures Following Cataract Surgery in Medicare Beneficiaries
Risk of Fractures Following Cataract Surgery in Medicare Beneficiaries Victoria L. Tseng, MD, Fei Yu, PhD, Flora Lum, MD, Anne L. Coleman, MD, PhD JAMA. 2012;308(5):493-501 Background Visual impairment
More informationSCALES SCALES SCALES. Performance Scales WHAT SHOULD THE RAINBOW FISH DO WITH ALL OF THESE SCALES?? KPS FAST ECOG PPS NYHA MRI ALSFRS
SCALES SCALES SCALES WHAT SHOULD THE RAINBOW FISH DO WITH ALL OF THESE SCALES?? Karen L. Cross, MD, FAAHPM Performance Scales KPS FAST ECOG PPS NYHA MRI ALSFRS PPS = 30, 40, or 50 ECOG = 2, 3, or 4 NYHA
More informationSECTION 1: INCLUSION, EXCLUSION & RANDOMISATION INFORMATION
SECTION 1: INCLUSION, EXCLUSION & RANDOMISATION INFORMATION DEMOGRAPHIC INFORMATION Given name Family name Date of birth Consent date Gender Female Male Date of surgery INCLUSION & EXCLUSION CRITERIA YES
More informationPalliative Care Clinical Research, Calvary and PaCCSC
Palliative Care Clinical Research, Calvary and PaCCSC Linda Brown, National Manager Palliative Care Clinical Studies Collaborative (PaCCSC) The mutually beneficial relationship between Calvary and PaCCSC
More informationPREMEDICATIONS: Antiemetic protocol for highly emetogenic chemotherapy. May not need any antiemetic with
BCCA Protocol Summary for Palliative Therapy of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, or Anal Squamous Cell Carcinoma using
More informationCommunity and Mental Health Services. Palliative Care. Criteria and
Community and Mental Health Services Specialist Palliative Care Service Referral Criteria and Guidance November 2018 Specialist Palliative Care Service Referrals These guidelines cover referrals for patients
More informationComparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments
Comparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments Prepared for: American Hospital Association April 4, 2019 Berna Demiralp,
More informationSynopsis. Study Phase and Title: Study Objectives: Overall Study Design
Synopsis Study Phase and Title: Study Objectives: Overall Study Design Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib
More informationSpecialist Palliative Care Service Referral Criteria and Guidance
Specialist Palliative Care Service Referral Criteria and Guidance Specialist Palliative Care Service Referrals These guidelines cover referrals for patients with progressive terminal illness, whether
More informationGENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):
Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS
More informationCare of the dying in End Stage Kidney Disease (ESKD) - Conservative. Elizabeth Josland Renal Supportive Care CNC St George Hospital
Care of the dying in End Stage Kidney Disease (ESKD) - Conservative Elizabeth Josland Renal Supportive Care CNC St George Hospital Introduction What does conservative management look like? How does the
More informationHeart Failure (HF) - Primary Care Flow Charts. Pre diagnosis Symptoms or signs suggestive of HF
Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange
More informationHeart Failure (HF) - Primary Care Flow Charts. Symptoms or signs suggestive of HF. Pre diagnosis. Refer to the Heart Failure Clinic at VHK for
Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange
More informationGuideline for Estimating Length of Survival in Palliative Patients
http://pal 11 ative. into Cornelius Woelk MD, CCFP Medical Director of Palliative Care Regional Health Authority - Central Manitoba 385 Main Street Winkler, Manitoba, Canada R6W 1J2 Ph: 204-325-4312 Fax:
More informationObjectives 2/11/2016 HOSPICE 101
HOSPICE 101 Overview Hospice History and Statistics What is Hospice? Who qualifies for services? Levels of Service The Admission Process Why Not to Wait Objectives Understand how to determine hospice eligibility
More informationAlliance A Symptomatic brain radionecrosis after receiving radiosurgery for
RANDOMIZED PHASE II STUDY: CORTICOSTEROIDS + BEVACIZUMAB VS. CORTICOSTEROIDS + PLACEBO (BEST) FOR RADIONECROSIS AFTER RADIOSURGERY FOR BRAIN METASTASES Pre-registration Eligibility Criteria Required Initial
More informationBACKGROUND Measuring renal function :
A GUIDE TO USE OF COMMON PALLIATIVE CARE DRUGS IN RENAL IMPAIRMENT These guidelines bring together information and recommendations from the Palliative Care formulary (PCF5 ) BACKGROUND Measuring renal
More informationAlzheimer s Disease, Dementia, Related Disorders
Alzheimer s Disease, Dementia, Related Disorders Stage 7 on the FAST Scale signifies the threshold of activity limitation that would support a six-month prognosis. The FAST Scale does not address the impact
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationUniversity of Bristol - Explore Bristol Research
Hunt, L., Ben-Shlomo, Y., Whitehouse, M., Porter, M., & Blom, A. (2017). The Main Cause of Death Following Primary Total Hip and Knee Replacement for Osteoarthritis: A Cohort Study of 26,766 Deaths Following
More informationPalliative Care Referral/Triage Tool
Palliative Care Referral/Triage Tool Gippsland Region Palliative Care Consortium Clinical Practice Group Title Keywords Ratified Palliative Care Referral/Triage Tool Palliative Care, triage, symptom assessment,
More informationMAKING THE NSQIP PARTICIPANT USE DATA FILE (PUF) WORK FOR YOU
MAKING THE NSQIP PARTICIPANT USE DATA FILE (PUF) WORK FOR YOU Hani Tamim, PhD Clinical Research Institute Department of Internal Medicine American University of Beirut Medical Center Beirut - Lebanon Participant
More informationECX. Anti-emetics: Day 1: highly emetogenic Days 2 21: mildly emetogenic
Page 1 of 5 As an alternative to ECF: For locally advanced (inoperable) or metastatic oesophageal or gastric cancer; peri-operative use in oesophageal or gastric cancer; adenocarcinoma of unknown primary
More informationDiscussing Prognosis. David Ross Russell MD ProHealth Physicians Inc.
Discussing Prognosis David Ross Russell MD ProHealth Physicians Inc. Prognosis- peeling back the layers Not a new Science Psalm 39 LORD, make me to know mine end, and the measure of my days. Hippocrates
More informationDetermining Eligibility for Hospice Care
Determining Eligibility for Hospice Care Main Number: 203 739-8300 Toll Free Number: 888 357-3334 www.regionalhospicect.org Many people may not understand all that Regional Hospice can offer or they are
More informationSpecialist Palliative Care Referral for Patients
Specialist Palliative Care Referral for Patients This guideline covers referrals for patients with progressive terminal illness, whether due to cancer or other disease. For many patients in the late stages
More informationTrastuzumab (IV) Monotherapy - 7 days
INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 7 days Regimen *Reimbursement INDICATION ICD10 Code Status Treatment of patients with HER2 positive metastatic breast cancer (MBC) C50 00201a Hospital
More informationEXACERBATION ASSESSMENT FORM
EXACERBATION ASSESSMENT FORM ID NUMBER: 0a) Form Completion Date... 0b) Staff Code... Administrative Information 1) Date of clinic visit: 2) What type of Event is this?... Participant/HCU-triggered...
More informationEXACERBATION ASSESSMENT FORM
EXACERBATION ASSESSMENT FORM ID NUMBER: VERSION: 1.0 05/27/14 0a) Form Completion Date... 0b) Staff Code... Instructions: This form should be completed when a participant comes to the clinical center for
More information532.6 (chronic or unspecified duodenal
Supplementary table 1: ICD-9 and ICD-10 codes used for the identification of major bleeding and endoscopy Bleeding episode type ICD-9 codes ICD-10 codes Intracranial 430 (Subarachnoid), 431 (intracerebral),
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More informationCapecitabine Oxaliplatin 21 day cycle (CAPOX)
Systemic Anti Cancer Treatment Protocol Oxaliplatin 21 day cycle (CAPOX) PROTOCOL REF: MPHACAPOX (Version No: 1.0) Approved for use in: Adjuvant colorectal cancer stage 3 or high risk stage 2 Advanced
More information11. NATIONAL DAFNE CLINICAL AND RESEARCH DATABASE
11. NATIONAL DAFNE CLINICAL AND RESEARCH DATABASE The National DAFNE Clinical and Research database was set up as part of the DAFNE QA programme (refer to section 12) to facilitate Audit and was updated
More informationTechnical appendix: The impact of integrated care teams on hospital use in North East Hampshire and Farnham
Improvement Analytics Unit September 2018 Technical appendix: The impact of integrated care teams on hospital use in North East Hampshire and Farnham Therese Lloyd, Richard Brine, Rachel Pearson, Martin
More informationSupplementary Online Content
Supplementary Online Content Khera R, Dharmarajan K, Wang Y, et al. Association of the hospital readmissions reduction program with mortality during and after hospitalization for acute myocardial infarction,
More informationThe structure of PCOC involves three levels. Definitions for each level can be found in this manual. Level 1: Patient level describes demographics
The PCOC Structure The standardisation of palliative care clinical data items and assessment tools serves the dual purpose of defining a common language to enhance communication between palliative care
More informationNES Asthma Hospital Medication Care Plan 7
NES Asthma Hospital Medication Care Plan 7 PATIENT DETAILS Name Liz Duncan Address Consultant Gender Female Weight 60kg Height 1.6m General Practitioner Dr Jones Community Pharmacist Date of Birth (Age)
More informationPILOT STUDY PROPOSAL FOR EARLY DISCHARGE OF LOW-RISK NEUTROPENIC PATIENTS
PILOT STUDY PROPOSAL FOR EARLY DISCHARGE OF LOW-RISK NEUTROPENIC PATIENTS RATIONALE: It is increasingly being recognised that not all neutropenic patients have the same risk of complications during episodes
More informationTrastuzumab emtansine Kadcyla
Trastuzumab emtansine Kadcyla Indication Treatment of HER2 positive unresectable locally advanced or metastatic breast cancer for patients who have previously received a taxane and trastuzumab (Herceptin
More informationTretinoin - ATRA (All Trans Retinoic Acid)
Tretinoin - ATRA (All Trans Retinoic Acid) Indication Treatment of acute promyelocytic leukaemia (APML) Used in combination with chemotherapy. ICD-10 codes C92.4 Regimen details APML induction therapy
More informationClinical Outcome in Patients with Aortic Stenosis
Clinical Outcome in Patients with Aortic Stenosis Is the Prognosis Worse in Patients with Low-Gradient Severe Aortic Stenosis? Yoel Angel BSc, Shemy Carasso MD, Diab Mutlak MD, Jonathan Lessick MD Dsc,
More informationEXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) REFERRAL FORM
Patient Label This form is accessible on www.royalpapworth.nhs.uk Intensive Care Unit EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) REFERRAL FORM Please always phone Papworth ECMO Coordinator on 01480 830541,
More informationPREOPERATIVE ANAEMIA PATHWAY
PREOPERATIVE ANAEMIA PATHWAY Surname: Patient ID No. Forename: DOB: / / Age: NHS Number: Likes to be called: Address: Tel. No. Religion/Spirituality: Next of Kin: Name GP Name: GP Practice: Planned Operation:
More informationExpanded Criteria Recipients: Are there any Limits
Expanded Criteria Recipients: Are there any Limits Andreas Paul, MD, MSc, FRCS Department of General-, Visceral- and Transplant Surgery, University Hospital Essen Ruhr Area 5.200 000 inhabitants University
More informationDERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:
OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community
More informationBRAVTPCARB. Protocol Code: Breast. Tumour Group: Dr. Karen Gelmon. Contact Physician:
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN), PACLitaxel and CARBOplatin as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour
More informationSubject ID: I N D # # U A * Consent Date: Day Month Year
IND Study # Eligibility Checklist Pg 1 of 15 Instructions: Check the appropriate box for each Inclusion and Exclusion Criterion below. Each criterion must be marked and all protocol criteria have to be
More informationOsimertinib Early Access Scheme
Systemic Anti Cancer Treatment Protocol Osimertinib Early Access Scheme PROTOCOL REF: MPHALUNOSI (Version No: 1.0) Approved for use in: In EGFR T970M mutation positive NSCLC who have progressed on or after
More informationOnline Supplementary Data. Country Number of centers Number of patients randomized
A Randomized, Double-Blind, -Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 21 days Regimen *Reimbursement INDICATION ICD10 Code Status HER2 positive metastatic breast cancer (MBC) C50 00200a Hospital HER2 positive early breast
More informationNICE Guidance. Suspected Cancer in Adults COLORECTAL (2WW)
NICE Guidance Suspected Cancer in Adults COLORECTAL (2WW) Date of Referral: Short date letter merged Name: Full Name DOB: Date of Birth NHS No NHS Number Attach this form to the e-referral within 24 hours
More informationTocilizumab Guided Questionnaire Myocardial Infarction/Acute Coronary Syndrome
Tocilizumab Guided Questionnaire Myocardial Infarction/Acute Coronary Syndrome AER: Site : Local Case ID: Patient Date of Birth (dd-mmm-yyyy): Patient ID/Initials: Patient Gender: M F Patient Weight kg
More informationSupplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.
Rationale, design, and baseline characteristics of the SIGNIFY trial: a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical
More informationRevision of 11/15/2017 Form # 249 Page 1 of 7 Pilot Clinical Trials in CKD Follow-Up Pill Dispensing and Counting Form # COMBINE
Revision of 11/15/2017 Form # 249 Page 1 of 7 Pilot Clinical Trials in CKD Follow-Up Pill Dispensing and Counting Form # 249 - COMBINE This form is completed for all Protocol visits and for any extra follow-up
More informationPlattenepithelkarzinom des Ösophagus, 1 st -line
Plattenepithelkarzinom des Ösophagus, 1 st -line AIO-STO-0309 An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced
More informationPatient enrolment details CKDOD registry
Patient enrolment details CKDOD registry Personal Information Date of enrolment D D Date of birth D D Gender Descent Height cm m History of smoking Y N U Date of first diagnosis of CKD D D Primary Cause
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationCycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline
BC Cancer Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab (HERCEPTIN), and PACLItaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code:
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More informationOntario s Referral and Listing Criteria for Adult Heart Transplantation
Ontario s Referral and Listing Criteria for Adult Heart Transplantation Version 3.0 Trillium Gift of Life Network Adult Heart Transplantation Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The
More informationPatient Group Direction for the Supply of Nitrofurantoin MR 100mg capsules
October 2016 Patient Group Direction for the Supply of Nitrofurantoin MR 100mg capsules This Patient Group Direction (PGD) is a specific written instruction for the supply and/or administration of nitrofurantoin
More informationSupplementary Online Content
Supplementary Online Content Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based
More informationResearch in Real Life. Real Life Effectiveness of Aclidinium Bromide. Version Date: 26 September 2013
Research in Real Life Real Life Effectiveness of Aclidinium Bromide Version Date: 26 September 2013 Project for Almirall Real-life effectiveness evaluation of the long-acting muscarinic antagonist aclidinium
More informationNCCP Chemotherapy Regimen. Afatinib Therapy
INDICATIONS FOR USE: Afatinib Therapy Regimen Code INDICATION ICD10 Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung
More informationCHF for Clinician. AtHomeCare.com
CHF for Clinician AtHomeCare.com CONTACT INFORMATION FOR CLIENTS Client s Name: SOC Date: Case Manager s Name: Phone #: Physician s Name: Phone: Emergency Contact Person s Name: Phone Number: MISSION STATEMENT
More informationSUPPLEMENTARY MATERIAL Risk of cancer in patients with thyroid disease and venous thromboembolism
SUPPLEMENTARY MATERIAL Risk of cancer in patients with thyroid disease and venous thromboembolism Diana H Christensen 1 Katalin Veres 1 Anne G Ording 1 Jens Otto L Jørgensen 2 Suzanne C Cannegieter 3 Reimar
More informationComorbidities and cancer Applications to non small cell lung cancer
Comorbidities and cancer Applications to non small cell lung cancer Pr A. Vergnenègre Dr H. Le Caer CHU Limoges CH Draguignan 1 Comorbidities and cancer Why? 2 Epidemiology elderly among lung cancer 2010-2014
More informationEOX. Advanced / metastatic use: 8 cycles (CT scan after cycles 4 and 8)
EOX Page 1 of 6 As an alternative to ECX: For locally advanced (inoperable) or metastatic oesophageal or gastric cancer For patients able to take oral medications Drugs/Dosage: Epirubicin 50mg/m 2 IV D1
More informationPsoriasis is associated with increased risk of incident Diabetes Mellitus: A Danish nationwide cohort study
Psoriasis is associated with increased risk of incident Diabetes Mellitus: A Danish nationwide cohort study Khalid U, Hansen PR, Gislason GH, Kristensen SL, Lindhardsen J, Skov L, Torp-Pedersen C, Ahlehoff
More informationObinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case
Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Available
More informationWhy is co-morbidity important for cancer patients? Di Riley Associate Director Clinical Outcomes Programme
Why is co-morbidity important for cancer patients? Di Riley Associate Director Clinical Outcomes Programme Co-morbidity in cancer Definition:- Co-morbidity is a disease or illness affecting a cancer patient
More informationMeasure #403: Adult Kidney Disease: Referral to Hospice National Quality Strategy Domain: Patient and Caregiver-Centered Experience and Outcomes
Measure #403: Adult Kidney Disease: Referral to Hospice National Quality Strategy Domain: Patient and Caregiver-Centered Experience and Outcomes 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationSupplementary Online Content
Supplementary Online Content Dharmarajan K, Wang Y, Lin Z, et al. Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA. doi:10.1001/jama.2017.8444 etable
More informationThe Prognostic Importance of Comorbidity for Mortality in Patients With Stable Coronary Artery Disease
Journal of the American College of Cardiology Vol. 43, No. 4, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.10.031
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationSAMPLE Data Entry Manual for the veds Project
The data entry manual is designed to provide a clear definition for each variable collected and the options for each variable SAMPLE Data Entry Manual for the veds Project Subject ID Each study participant
More informationSUPPLEMENTAL MATERIALS
SUPPLEMENTAL MATERIALS Table S1: Variables included in the propensity-score matching Table S1.1: Components of the CHA 2DS 2Vasc score Table S2: Crude event rates in the compared AF patient cohorts Table
More informationGeriatric screening in acute care wards a novel method of providing care to elderly patients
Geriatric screening in acute care wards a novel method of providing care to elderly patients JKH Luk, T Kwok, J Woo Objective. To assess a nurse-implemented geriatric screening system. Design. Descriptive
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg. Date of FAR:
Core Safety Profile Active substance: Bisoprolol Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg P - RMS: FI/H/PSUR/0002/002 Date of FAR: 13.12.2011
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationCapecitabine Oxaliplatin 21 day cycle (XELOX)
Systemic Anti Cancer Treatment Protocol Capecitabine Oxaliplatin 21 day cycle (XELOX) PROTOCOL REF: MPHAXELOX (Version No: 1.0) Approved for use in: Adjuvant colorectal cancer stage 3 or high risk stage
More informationComorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia
Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF
More informationWestern Locality Shared care Information ~ Penicillamine, Rheumatology April 2013
Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to
More informationHospice Eligibility August 2018
Hospice Eligibility August 2018 Objectives Identify who can make a hospice referral Review hospice eligibility and disease-specific prognostic indicators Review Open Access philosophy Who Can Make A Referral
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON EVALUATION OF ANTICANCER MEDICINAL PRODUCTS IN MAN
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 24 July 2003 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON EVALUATION
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationTransitions Guidelines: Chronic Illness Management. Revised 2016
Transitions Guidelines: Chronic Illness Management Revised 2016 1 Table of Contents Introduction Transitions Program Pillars General Principles Regarding Admission Cancer Cirrhosis Congestive Heart Failure
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationGuide to completing the MODET study CRF
Guide to completing the MODET study CRF Please record ND for not documented, NA for not applicable and UK for unknown rather than leave blank fields. CRF PAGE 1. Time of injury Complete the time of injury
More informationNCCP Chemotherapy Regimen. Epirubicin, Oxaliplatin and Capecitabine (EOX) -21 day
INDICATIONS FOR USE: Epirubicin, Oxaliplatin and Capecitabine (EOX) -21 day Regimen INDICATION ICD10 Code Locally advanced or metastatic gastric carcinoma C16 00239a Locally advanced or metastatic oesophageal
More informationNICE Chronic Heart Failure Guidelines in Adults 2018
NICE Chronic Heart Failure Guidelines in Adults 2018 The Whys, Whats and Hows of the importance of effectively managing heart failure in Primary Care and the community. Foreword Dr Clare J Taylor, General
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More information